ATRC — Q2 2026 Financial Report Analysis

Overview

AtriCure makes surgical tools for atrial fibrillation (AFib, an irregular heartbeat that raises stroke risk): clamps and probes that "ablate" (scar) heart tissue to stop faulty electrical signals, the AtriClip that seals off the left atrial appendage (a small pouch where stroke-causing clots tend to form), and cryoSPHERE probes that freeze nerves to block pain after chest surgery. In the second quarter of 2026 (April–June) revenue rose 12.8% to $153.6 million and the company swung to a GAAP net profit of $9.0 million from a $6.2 million loss a year earlier. Growth came from three newer products — the cryoSPHERE MAX pain probe, the EnCompass ablation clamp and the smaller AtriClip FLEX-Mini/PRO-Mini clips — while the one shrinking business, minimally invasive "Hybrid" ablation, fell 21% as heart rhythm specialists switch to pulsed field ablation (PFA) catheters instead.

At a glance

• Revenue +12.8% to $153.6M (12.4% excluding currency moves) — growth held in the low teens for another quarter, with the U.S. (82% of sales) up 13.6%.
• Operating income of $9.7M vs a $6.2M loss — but $5.0M of that swing is a one-off: last year's quarter carried a $5.0M PFA development milestone payment. Even without it, operating profit improved by about $10.9M.
• Full-year guidance raised: adjusted EBITDA now $85–89M (was $80–82M in February) and GAAP EPS $0.05–0.13 (was $0.00–0.04), with the revenue range nudged up to $602–610M.

Key metrics

Year to date (six months), revenue was $294.9M (+13.5%) and net income $9.1M versus a $12.9M loss.

Where the growth came from

AtriCure reports revenue by four product franchises, split between the U.S. and international markets:

• Pain management is the fastest grower. U.S. pain management revenue rose 27.8% to $27.1M, which the 10-Q attributes to the cryoSPHERE MAX probe. It is now a fifth of company revenue and added $6.2M of the $17.5M total increase — more than any franchise except appendage management ($8.1M).
• Appendage management and open ablation are the core of the business: both are mostly used "concomitantly," meaning during an open-heart operation the patient is already having (e.g. a valve repair or bypass). U.S. appendage revenue grew 14.4% on the FLEX-Mini and PRO-Mini clips; U.S. open ablation grew 12.1% on the EnCompass clamp.
• Minimally invasive ablation keeps shrinking. U.S. revenue in this franchise fell 23.1% to $6.0M. Management states plainly that this is "continued reduction in Hybrid procedures as physicians adopt PFA catheters." PFA is a newer catheter technique electrophysiologists use without surgery, and it is taking patients who would previously have had AtriCure's surgical-plus-catheter Hybrid procedure. At 5% of revenue the drag is now small, but it is a real share loss to a competing approach.
• International growth was flattered by currency. International sales rose 9.6% as reported but 7.1% at constant currency (i.e. using last year's exchange rates), so about 2.5 points came from a weaker dollar rather than more devices sold.

Why profit jumped

Three things moved operating income from a $6.2M loss to a $9.7M profit:

1. Gross margin up 269 basis points to 77.2%. Cost of revenue rose only $0.3M while revenue rose $17.5M. The 10-Q credits "favorable product and geographic mix, along with manufacturing efficiencies" — more higher-margin U.S. sales and newer products.
2. A one-off in the comparison. R&D fell $2.9M (to $26.4M), but only because Q2 2025 included a $5.0M milestone payment under AtriCure's PFA co-development agreement. Underlying R&D actually rose about $2.1M (product development +$0.8M, regulatory filings +$0.8M, staff +$0.5M).
3. Selling and admin costs grew more slowly than sales: SG&A rose 5.3% ($4.2M, mostly headcount, training and IT) against 12.8% revenue growth, so SG&A fell from 57.6% to 53.8% of revenue. This is operating leverage — fixed-ish costs being spread over more sales.

What the headline numbers hide

• The profit swing is partly a comparison effect. Of the $15.9M improvement in operating income, $5.0M is last year's PFA milestone not recurring. Strip it out and Q2 2025's operating loss would have been about $1.2M, so the like-for-like improvement is roughly $10.9M — still large, but smaller than the headline.
• GAAP vs adjusted. This quarter adjusted EPS equals GAAP EPS ($0.18), because the only adjustment AtriCure makes to EPS (the milestone) didn't occur. Adjusted EBITDA of $27.3M is far higher than the $9.7M operating profit because it adds back $12.3M of share-based compensation (stock paid to employees, 8.0% of revenue) and $5.3M of depreciation and amortization. Stock pay is a real cost to shareholders — it shows up as dilution: diluted shares rose 2.4% year over year to 48.9M, and there are no buybacks offsetting it (the only repurchases, $11.8M year to date, are shares withheld to cover employees' taxes on vesting stock).
• Cash conversion is positive but working capital absorbed a lot. Six-month operating cash flow was $18.2M against $9.1M of net income — higher than profit only because stock pay ($23.6M) is non-cash. Receivables rose to $80.0M from $66.7M at year-end (+20% vs +13.5% revenue growth year to date), and inventory to $83.9M from $78.5M; together they absorbed $19.4M of cash in the half, versus $4.9M a year earlier. Management says receivables rose "from increased sales" and inventory is being built "to support future growth." After $7.6M of capital spending, six-month free cash flow was about $10.6M, and cash ended June at $167.8M (vs $167.4M at year-end) with $61.0M of debt. The company reported $21.6M of "cash generation" in Q2 alone, meaning Q1 was a cash-using quarter.
• No help from tax or interest. Income tax was just $0.5M and net interest a $0.1M cost, so EPS reflects operations, not financial items.
• Guidance moved up meaningfully on profit, slightly on revenue (see below).

Takeaway: AtriCure has crossed into GAAP profitability on the back of a 77% gross margin and costs growing slower than sales, not just accounting adjustments — but about a third of the year-over-year profit swing is a lapped $5.0M milestone, and the raised full-year guide implies second-half adjusted EBITDA of roughly $41–45M, about flat with the first half's $44.4M rather than accelerating.

Outlook

Management's guidance (July 23, 2026), compared with the February guidance:

Against full-year 2025 revenue of $534.5M, the new range means 12.6%–14.1% growth. With $294.9M already booked in the first half, it implies second-half revenue of about $307–315M, or roughly 12%–15% growth over the second half of 2025 — consistent with the pace so far rather than a step up.

Our read. The near-term picture is steady: three growing franchises (pain, appendage, open ablation) covering 95% of revenue, with the Hybrid decline now too small to move the total much. The guidance raise is mostly about margin, and the first half already delivered more than half of the new adjusted EBITDA range, so the target looks reachable unless second-half spending rises sharply. The bigger swing factors are further out: results from the LeAAPS trial (6,573 patients enrolled by July 2025, testing whether sealing the appendage during heart surgery prevents strokes in patients without AFib) and BoxX-NoAF, which could widen the pool of surgical patients for the AtriClip and EnCompass clamp — but LeAAPS requires at least five years of follow-up. The 10-Q also flags that "new entrants" are targeting AtriCure's markets, which could pressure pricing. Things to watch next quarter: whether receivables growth slows back toward sales growth, the European launch of the FLEX-Mini/PRO-Mini clips (CE mark received April 2026, launch expected later this year), and how much further minimally invasive ablation falls.

Source: AtriCure Form 10-Q for the quarter ended June 30, 2026 (filed July 27, 2026), and the Q2 2026 earnings release (Form 8-K, Exhibit 99.1, July 23, 2026) for adjusted EBITDA and guidance.